# A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

> **NCT04262804** · PHASE2 · UNKNOWN · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 123 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Margetuximab
- **DRUG:** Trastuzumab
- **DRUG:** Chosen Chemotherapy (Capecitabine)
- **DRUG:** Chosen Chemotherapy (Vinorelbine )
- **DRUG:** Chosen Chemotherapy (Gemcitabine )

## Key facts

- **NCT ID:** NCT04262804
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-13
- **Primary completion:** 2021-09-03
- **Final completion:** 2023-12
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262804, "A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04262804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*